Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Clinical Trial of Once-Daily Raltegravir Now Underway

Merck announced this week that treatment-naive participants are now being enrolled in the Phase 3 ONCEMRK trial, which is evaluating the efficacy and safety of a ne formulation of the HIV integrase inhibitor raltegravir (Isentress) taken once rather than twice daily.

alt

Read more:

HIV and Hepatitis C Highlights from CROI 2014

Latest Positive Pulse Newsletter

In this overview, Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss selected highlights from the recent Conference on Retroviruses and Opportunistic Infections (CROI 2014), focusing on antiretroviral therapy, HIV cure research, and new treatments for hepatitis C and HIV/HCV coinfection.

alt

Read more:

CROI 2014: Disparities in Viral Suppression in Washington, DC [VIDEO]

A majority of people with HIV in Washington, DC, were able to achieve and maintain undetectable HIV viral load on antiretroviral therapy, but disparities in viral suppression exist with regard to race, sex, social, and economic factors, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

Earlier Antiretroviral Therapy Lowers Risk of Progression to AIDS and Related Conditions

Starting antiretroviral therapy (ART) at higher CD4 cell levels can significantly reduce the risk of AIDS-related clinical events, especially tuberculosis, as well as dramatically reducing the likelihood of HIV sexual transmission, according to findings from the HPTN 052 study published in the April 2014 issue of Lancet Infectious Diseases.

alt

Read more:

CROI 2014: Raltegravir Has Edge Over 2 HIV Protease inhibitors in 3-Drug Comparison

In a head-to-head comparison of 3 drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) last week in Boston, the integrase inhibitor raltegravir (Isentress) proved to be superior, in terms of the overall likelihood of treatment failure, when compared to 2 ritonavir-boosted protease inhibitors, atazanavir (Reyataz) and darunavir (Prezista).

alt

Read more:

Updated Antiretroviral Treatment Guidelines Include Cost Considerations

The U.S. Department of Health and Human Services (DHHS) this week released an update to its Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Among the major changes are the addition of a new section on cost considerations and a recommendation for less frequent CD4 T-cell monitoring for people without advanced disease.

alt

Read more:

CROI 2014: Early Treatment Reduces Viral Reservoirs but Does Not Prevent Rebound

Antiretroviral therapy started during the first several days after infection limited dissemination of an HIV-like virus throughout the body and establishment of cellular and tissue reservoirs in monkeys, though it did not prevent the virus from coming back after stopping treatment, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more: